{"product_id":"cancer-consult-9781118589212","title":"Cancer Consult","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003ci\u003eList of Contributors, x\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePreface, xxi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 1 Malignant Hematology and Hematopoietic Cell Transplantation\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 Acute Lymphoblastic Leukemia in Adults\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Diagnosis of acute lymphoblastic leukemia, 5\u003cbr\u003e \u003ci\u003eFrederick G. Behm, Agatha Bogard, Syed A. Abutalib, and Sujata S. Gaitonde\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Prognostic markers and models in acute lymphoblastic leukemia, 18\u003cbr\u003e \u003ci\u003eDieter Hoelzer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Management of B-cell acute lymphoblastic leukemia, 22\u003cbr\u003e \u003ci\u003eHady Ghanem, Hagop Kantarjian, Nitin Jain, and Elias Jabbour\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Management of T-cell acute lymphoblastic leukemia, 29\u003cbr\u003e \u003ci\u003eDaniel J. DeAngelo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Minimal residual disease in acute lymphoblastic leukemia, 35\u003cbr\u003e \u003ci\u003eMeir Wetzler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Hematopoietic cell transplantation in adult acute lymphoblastic leukemia, 40\u003cbr\u003e \u003ci\u003eNetanel A. Horowitz and Jacob M. Rowe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Acute Myeloid Leukemia in Adults\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7 Prognosis in acute myeloid leukemia: cytogenetics and beyond, 51\u003cbr\u003e \u003ci\u003eGordana Raca, Madina Sukhanova, and Lucy A. Godley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Induction therapy in acute myeloid leukemia, 58\u003cbr\u003e \u003ci\u003eTapan Kadia and Farhad Ravandi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Consolidation therapy in acute myeloid leukemia, 67\u003cbr\u003e \u003ci\u003eGregory K. Behbehani and Bruno C. Medeiros\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Management of acute promyelocytic leukemia, 71\u003cbr\u003e \u003ci\u003eEytan M. Stein and Martin S. Tallman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Minimal residual disease in acute myeloid leukemia, 76\u003cbr\u003e \u003ci\u003eHans Beier Ommen, Line Nederby, Marie Toft-Petersen, Charlotte Guldborg Nyvold, and Peter Hokland\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Relapsed and refractory acute myeloid leukemia, 82\u003cbr\u003e Stefan H. Faderl\u003c\/p\u003e \u003cp\u003e13 Hematopoietic cell transplantation in acute myeloid leukemia, 89\u003cbr\u003e \u003ci\u003eAntonio M. Jimenez and Stefan O. Ciurea\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Myelodysplastic Syndromes and Related Disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e14 Pitfalls in the diagnosis of myelodysplastic syndromes, 99\u003cbr\u003e \u003ci\u003eJay Yang, Gail Bentley, and Charles A. Schiffer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Cytogenetics and prognostic models in myelodysplastic syndromes, 106\u003cbr\u003e \u003ci\u003eUma Borate and Harry P. Erba\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Management of myelodysplastic syndromes, 113\u003cbr\u003e \u003ci\u003eVu H. Duong, Alan F. List, and Rami S. Komrokji\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Management of therapy-related myeloid neoplasms, 120\u003cbr\u003e \u003ci\u003eJagoda K. Jasielec and Richard A. Larson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Hematopoietic cell transplantation in myelodysplastic syndromes, 126\u003cbr\u003e \u003ci\u003eAntonio Di Stasi, Armin Ghobadi, and Partow Kebriaei\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Acquired aplastic anemia, 131\u003cbr\u003e \u003ci\u003eValeria Visconte and Ramon V. Tiu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4 Myeloproliferative Neoplasms\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e20 Diagnostic approach in myeloproliferative neoplasms, 137\u003cbr\u003e \u003ci\u003eAyalew Tefferi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Chronic myeloid leukemia: chronic phase, 142\u003cbr\u003e \u003ci\u003eJerald P. Radich\u003c\/i\u003e\u003cbr\u003e \u003cbr\u003e 22 Blast crisis of chronic myeloid leukemia, 147\u003cbr\u003e \u003ci\u003eMichael J. Mauro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Chronic myeloid leukemia and pregnancy, 150\u003cbr\u003e \u003ci\u003eMichael J. Mauro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Polycythemia vera, 152\u003cbr\u003e \u003ci\u003eConstantine S. Tam and Srdan Verstovsek\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Essential thrombocytosis, 156\u003cbr\u003e \u003ci\u003ePaola Guglielmelli and Alessandro M. Vannucchi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Primary myelofibrosis, 162\u003cbr\u003e \u003ci\u003eAyalew Tefferi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Eosinophilic myeloproliferative disorders, 167\u003cbr\u003e \u003ci\u003eJason Gotlib\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Chronic myelomonocytic leukemia, 176\u003cbr\u003e \u003ci\u003eMrinal M. Patnaik\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Hematopoietic cell transplantation in chronic myeloid leukemia, 180\u003cbr\u003e \u003ci\u003eJerald P. Radich\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Hematopoietic cell transplantation in primary myelofibrosis, 187\u003cbr\u003e \u003ci\u003eIrum Khan and Damiano Rondelli\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5 Chronic Lymphocytic and Other Leukemias\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e31 Prognostic markers and management of chronic lymphocytic leukemia, 195\u003cbr\u003e \u003ci\u003eCourtney D. DiNardo and Susan O’Brien\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 Hematopoietic cell transplantation in chronic lymphocytic leukemia, 201\u003cbr\u003e \u003ci\u003eMichael R. Bishop\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Prolymphocytic leukemia, 207\u003cbr\u003e \u003ci\u003eClaire Dearden\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Hairy cell leukemia, 220\u003cbr\u003e \u003ci\u003eJustin M. Watts and Martin S. Tallman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 6 Hodgkin Lymphoma\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e35 Management of classical Hodgkin lymphoma, 229\u003cbr\u003e \u003ci\u003eKristen Sanfi lippo and Nancy L. Bartlett\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 Nodular lymphocyte-predominant Hodgkin lymphoma, 235\u003cbr\u003e \u003ci\u003eDennis A. Eichenauer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 Hematopoietic cell transplantation in Hodgkin lymphoma, 240\u003cbr\u003e \u003ci\u003eTsiporah Shore and Koen van Besien\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 7 Non-Hodgkin’s Lymphomas\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e38 Pitfalls in the diagnosis of non-Hodgkin’s lymphomas, 247\u003cbr\u003e \u003ci\u003eCarmen Barcena and Laurence de Leval\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e39 Follicular lymphoma, 257\u003cbr\u003e \u003ci\u003eMyron S. Czuczman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e40 Diffuse large B-cell lymphoma, 263\u003cbr\u003e \u003ci\u003eAndrew D. Zelenetz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e41 Mantle cell lymphoma, 270\u003cbr\u003e \u003ci\u003eStephen Smith and John Sweetenham\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e42 Marginal zone lymphoma, 275\u003cbr\u003e \u003ci\u003eSarah Rutherford, Wayne Tam, and Peter Martin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e43 Primary mediastinal large B-cell lymphoma, 282\u003cbr\u003e \u003ci\u003ePier Luigi Zinzani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e44 Burkitt lymphoma, 286\u003cbr\u003e \u003ci\u003eMark Roschewski and Wyndham Wilson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e45 Gray zone lymphoma, 290\u003cbr\u003e \u003ci\u003eCaron A. Jacobson and Ann S. LaCasce\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e46 Transformed lymphoma, 295\u003cbr\u003e \u003ci\u003eStephane Doucet and Jane N. Winter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e47 HIV-associated lymphoma, 304\u003cbr\u003e \u003ci\u003eKieron Dunleavy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e48 Primary CNS lymphoma, 308\u003cbr\u003e \u003ci\u003eNicholas A. Blondin, Joachim M. Baehring, and Fred H. Hochberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e49 Primary cutaneous lymphoma, 316\u003cbr\u003e \u003ci\u003eThomas M. Habermann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e50 Mycosis fungoides and Sézary syndrome, 323\u003cbr\u003e \u003ci\u003eStephane Dalle, Marie Perier-Muzet, Brigitte Balme, and Luc Thomas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e51 Hematopoietic cell transplantation in indolent non-Hodgkin’s lymphoma, 327\u003cbr\u003e \u003ci\u003eSaurabh Chhabra and Ginna G. Laport\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e52 Hematopoietic cell transplantation in diffuse large B-cell lymphoma, 332\u003cbr\u003e \u003ci\u003eSyed A. Abutalib and Istvan Redei\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e53 Hematopoietic cell transplantation in T-cell non-Hodgkin’s lymphomas, 339\u003cbr\u003e \u003ci\u003eLori S. Muffly and Sonali M. Smith\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 8 Plasma Cell Neoplasms and Related Disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e54 Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance, 347\u003cbr\u003e \u003ci\u003eRobert A. Kyle\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e55 Risk stratification and response assessment in multiple myeloma and Waldenström’s macroglobulinemia, 352\u003cbr\u003e \u003ci\u003eSilvia Gentili and Sagar Lonial\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e56 Treatment of multiple myeloma, 358\u003cbr\u003e \u003ci\u003eCindy Varga, Claudia Paba Prada, Kenneth Anderson, and Paul Richardson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e57 Light-chain amyloidosis, 366\u003cbr\u003e \u003ci\u003eDavid C. Seldin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e58 Waldenström’s macroglobulinemia, 371\u003cbr\u003e \u003ci\u003eAnita D’Souza and Morie A. Gertz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e59 Autologous hematopoietic cell transplantation in multiple myeloma, 376\u003cbr\u003e \u003ci\u003eJean-Luc Harousseau and Mohamad Mohty\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e60 Allogeneic hematopoietic cell transplantation in multiple myeloma, 381\u003cbr\u003e \u003ci\u003eJasleen Randhawa, Veerpal Singh, and Parameswaran Hari\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 9 Special Issues in Hematology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e61 Role of PET scan in lymphomas, 391\u003cbr\u003e \u003ci\u003eMatthew A. Lunning and James O. Armitage\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e62 Radioimmunotherapy in lymphomas, 398\u003cbr\u003e \u003ci\u003eReem Karmali and Stephanie A. Gregory\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e63 Radiation oncology consultation for hematologic malignancies, 403\u003cbr\u003e \u003ci\u003eChris R. Kelsey and Leonard R. Prosnitz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 10 Special Issues in Hematopoietic Cell Transplantation\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e64 Donor and graft selection in allogeneic hematopoietic cell transplantation, 411\u003cbr\u003e \u003ci\u003eJose Leonel Ochoa-Bayona and Claudio Anasetti\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e65 Preparative regimens in allogeneic hematopoietic cell transplantation for malignant hematological\u003cbr\u003e diseases, 417\u003cbr\u003e \u003ci\u003eRobert J. Soiffer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e66 T-cell depletion in allogeneic hematopoietic cell transplantation, 421\u003cbr\u003e \u003ci\u003eJenna D. Goldberg and Miguel-Angel Perales\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e67 Prevention and treatment of relapse following hematopoietic cell transplantation, 426\u003cbr\u003e \u003ci\u003eRobert Chen, Sandra Thomas, and Stephen J. Forman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e68 Acute graft-versus-host disease, 432\u003cbr\u003e \u003ci\u003eAndrew C. Harris and John E. Levine\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e69 Chronic graft-versus-host disease, 438\u003cbr\u003e \u003ci\u003eCarrie L. Kitko and Daniel R. Couriel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 2 Oncology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 Central Nervous System Tumors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e70 Primary brain tumors, 449\u003cbr\u003e \u003ci\u003eBarbara J. O’Brien and Mark R. Gilbert\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e71 Secondary brain and spinal cord tumors, 457\u003cbr\u003e \u003ci\u003eRimas V. Lukas, Patrik Gabikian, and Steven J. Chmura\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Head and Neck Cancers and Thoracic Malignancies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e72 Medical management of head and neck cancers, 467\u003cbr\u003e \u003ci\u003eTobenna Nwizu and David Adelstein\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e73 Endocrine malignancies, 476\u003cbr\u003e \u003ci\u003eAnn W. Gramza\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e74 Methodological and practical challenges for personalized therapies in non-small-cell lung cancer, 480\u003cbr\u003e \u003ci\u003eIgnacio I. Wistuba\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e75 Screening, staging, and stage I non-small-cell lung cancer, 486\u003cbr\u003e \u003ci\u003eTarek M. Mekhail\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e76 Stage II and III non-small-cell lung cancer, 493\u003cbr\u003e \u003ci\u003eGrzegorz Korpanty and Natasha B. Leighl\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e77 Recurrent and metastatic non-small-cell lung cancer and novel targets, 500\u003cbr\u003e \u003ci\u003eEvan Pisick and Ravi Salgia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e78 Small-cell lung cancer, 503\u003cbr\u003e \u003ci\u003eStephen V. Liu and Glen J. Weiss\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e79 Mesothelioma, 506\u003cbr\u003e \u003ci\u003eChristopher W. Towe and Harvey I. Pass\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Breast Cancer\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e80 Immunohistochemistry testing and beyond in breast cancer, 515\u003cbr\u003e \u003ci\u003eAlejandro A. Gru and D. Craig Allred\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e81 Prevention and adjuvant therapy in breast cancer, 523\u003cbr\u003e \u003ci\u003eFaithlore P. Gardner and Edith A. Perez\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e82 Preoperative systemic therapy for breast cancer, 532\u003cbr\u003e \u003ci\u003eVirginia Kaklamani and William J. Gradishar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e83 Recurrent and metastatic breast cancer, 540\u003cbr\u003e \u003ci\u003eDennis L. Citrin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e84 Special issues in the young and pregnant patient with breast cancer, 546\u003cbr\u003e \u003ci\u003eHatem A. Azim Jr. and Fedro A. Peccatori\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4 Gastrointestinal Oncology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e85 Early-stage esophageal and stomach cancers, 555\u003cbr\u003e \u003ci\u003eM. Naomi Horiba and Yixing Jiang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e86 Metastatic esophagogastric cancer: controversies, consensus, and new targets, 562\u003cbr\u003e \u003ci\u003eGeoffrey Y. Ku and David H. Ilson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e87 Early-stage colorectal cancer, 567\u003cbr\u003e \u003ci\u003eVaibhav Sahai and Al B. Benson III\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e88 Recurrent and metastatic colorectal cancer: controversies, consensus, and new targets, 573\u003cbr\u003e \u003ci\u003eDavendra Sohal and Robert J. Pelley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e89 Pancreatic cancer, 581\u003cbr\u003e \u003ci\u003eKatherine Van Loon and Margaret Tempero\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e90 Hepatobiliary cancer, 590\u003cbr\u003e \u003ci\u003eKeith Stuart\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e91 Neuroendocrine tumors, 595\u003cbr\u003e \u003ci\u003eAnya Litvak and Leonard Saltz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e92 Transarterial liver-directed therapies in oncology, 601\u003cbr\u003e \u003ci\u003eDivyesh G. Mehta and Jeffery Choh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e93 Anal cancer, 606\u003cbr\u003e \u003ci\u003eRob Glynne Jones\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5 Genitourinary Oncology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e94 Renal cancer: tumor diversity, molecular taxonomy, and prognostic algorithms, 615\u003cbr\u003e \u003ci\u003eHenry J. Conter and Eric Jonasch\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e95 Medical management of renal cancer, 621\u003cbr\u003e \u003ci\u003eGary R. MacVicar and Timothy M. Kuzel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e96 Medical management of bladder cancer, 628\u003cbr\u003e \u003ci\u003eGary R. MacVicar and Timothy M. Kuzel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e97 Prostate cancer: Screening, surveillance, prognostic algorithms and independent pathologic predictive\u003cbr\u003e parameters, 634\u003cbr\u003e \u003ci\u003eMegan G. Lockyer and Thomas M. Wheeler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e98 Medical management of prostate cancer, 638\u003cbr\u003e \u003ci\u003eElizabeth K. O’Donnell and Philip Kantoff\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e99 Germ cell tumors, 645\u003cbr\u003e \u003ci\u003eTimothy Gilligan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 6 Skin Malignancies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e100 Medical management of melanoma, 653\u003cbr\u003e \u003ci\u003eAna M. Ciurea and Kim Margolin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e101 Nonmelanoma skin cancers, 661\u003cbr\u003e \u003ci\u003eDaniel Christiansen and Anna Sancho Clayton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 7 Gynecological Malignancies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e102 Ovarian cancer: neoadjuvant, adjuvant, and surgical issues, 669\u003cbr\u003e \u003ci\u003eAlpa M. Nick and Robert L. Coleman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e103 Ovarian cancer: second-line treatment strategies, 675\u003cbr\u003e \u003ci\u003eMaurie Markman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e104 Endometrial and cervical cancers, 681\u003cbr\u003e \u003ci\u003eMaurie Markman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 8 Sarcomas\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e105 Bone sarcomas, 689\u003cbr\u003e \u003ci\u003eNicole Larrier, William C. Eward, and Richard F. Riedel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e106 Soft tissue sarcomas, 696\u003cbr\u003e \u003ci\u003eNeeta Somaiah and Shreyaskumar Patel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 9 Multidisciplinary Approach: Consultation with Surgical Oncology Team\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e107 Surgical aspects of head and neck cancers, 707\u003cbr\u003e \u003ci\u003eConstance E.H. Teo and Randal S. Weber\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e108 Surgical aspects of thoracic malignancies, 711\u003cbr\u003e \u003ci\u003eAlbert S.Y. Chang, Thomas A. D’Amico, and David C. White\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e109 Surgical aspects of upper gastrointestinal cancers, 719\u003cbr\u003e \u003ci\u003eSabha Ganai and Mitchell C. Posner\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e110 Surgical aspects of pancreatic cancer, 723\u003cbr\u003e \u003ci\u003eAmanda B. Cooper, Ching-Wei D. Tzeng, and Matthew H.G. Katz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e111 Surgical aspects of hepatobiliary tumors, 729\u003cbr\u003e \u003ci\u003eSubhasis Misra and Leonidas Koniaris\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e112 Surgical aspects of lower gastrointestinal cancers, 735\u003cbr\u003e \u003ci\u003eAnthony J. Senagore\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e113 Surgical aspects of renal cancer, 739\u003cbr\u003e \u003ci\u003eMichael E. Woods and Matthew C. Raynor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e114 Surgical aspects of bladder cancer, 744\u003cbr\u003e \u003ci\u003eMichael B. Williams\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e115 Surgical aspects of prostate cancer, 747\u003cbr\u003e \u003ci\u003ePeter Pinto\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e116 Surgical aspects of melanoma, 754\u003cbr\u003e \u003ci\u003eThomas Velancia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 10 Multidisciplinary Approach: Consultation with Radiation Oncology Team\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e117 Radiotherapy for head and neck cancers, 761\u003cbr\u003e \u003ci\u003eShiyu Song\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e118 Radiotherapy for ductal carcinoma in situ (DCIS), 767\u003cbr\u003e \u003ci\u003eBeryl McCormick\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e119 Radiotherapy for early-stage invasive breast cancer, 771\u003cbr\u003e \u003ci\u003eJulia White\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e120 Radiotherapy for thoracic malignancies, 778\u003cbr\u003e \u003ci\u003eMeredith E. Giuliani and Andrea Bezjak\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e121 Radiotherapy for gastrointestinal malignancies, 785\u003cbr\u003e \u003ci\u003eManisha Palta, Christopher Willett, and Brian Czito\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e122 Radiotherapy for genitourinary malignancies, 789\u003cbr\u003e \u003ci\u003eChristina H. Chapman and Curtiland Deville\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 11 Hereditary Cancer Syndromes and Genetic Testing in Oncology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e123 When to suspect hereditary cancer syndromes, 795\u003cbr\u003e \u003ci\u003eEmily Dalton and Kathy Schneider\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e124 Hereditary breast cancer syndromes, 800\u003cbr\u003e \u003ci\u003eKathy Schneider and Emily Dalton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e125 Genetic testing in gastrointestinal tumors, 804\u003cbr\u003e \u003ci\u003eKristen M. Shannon and Daniel C. Chung\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e126 Hereditary urogenital cancer syndromes, 810\u003cbr\u003e \u003ci\u003eMelanie Corbman and Eric Fowler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 12 Special Issues in Hematology and Oncology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e127 Carcinoma of unknown primary (CUP), 817\u003cbr\u003e \u003ci\u003eIsabella C. Glitza and Gauri R. Varadhachary\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e128 Geriatric oncology, 822\u003cbr\u003e \u003ci\u003eNayana Kamath and Supriya Gupta Mohile\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e129 Nuts and bolts of cancer immunotherapy, 826\u003cbr\u003e \u003ci\u003eChristopher R. Heery and James L. Gulley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e130 Controversies related to oncology clinical trial development, 831\u003cbr\u003e \u003ci\u003eElihu H. Estey\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e131 PET scan in oncology, 835\u003cbr\u003e \u003ci\u003eShaunagh McDermott and Michael A. Blake\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e132 Hematopoietic growth factors, 841\u003cbr\u003e \u003ci\u003eLeAnn B. Norris, Jametta Magwood, and Charles L. Bennett\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e133 Anticoagulation issues in oncology, 844\u003cbr\u003e \u003ci\u003eSteven M. Corsello and Jean Marie Connors\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e134 Symptom management and palliative care, 851\u003cbr\u003e \u003ci\u003eRony Dev and Eduardo D. Bruera\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e135 Metabolic and nutritional issues in oncology, 860\u003cbr\u003e \u003ci\u003eJulia Fechtner, Carolyn Lammersfeld, Carol Ireton-Jones, and Pankaj Vashi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e136 Bone-related issues in oncology, 867\u003cbr\u003e \u003ci\u003eS. Mujtaba Rizvi, Helen Collins, and Alan Lipton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e137 Integrative medicine in oncology, 872\u003cbr\u003e \u003ci\u003eWeidong Lu and David S. Rosenthal\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e138 Naturopathic medicine in oncology, 879\u003cbr\u003e \u003ci\u003eChristina M. Shannon, Tracey Thomas, and Shauna Birdsall\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e139 Anesthesiology consultation for localized cancer pain, 884\u003cbr\u003e \u003ci\u003eAbed Rahman, Magdalena Anitescu, and Raed Rahman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e140 Musculoskeletal care in oncology, 893\u003cbr\u003e \u003ci\u003eJames E. Rosenberg and Charles A. McDonald\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e141 Cancer survivorship and psychosocial issues in oncology, 896\u003cbr\u003e \u003ci\u003eJabeen Abutalib, Shahid Raza, and Laura Sunn\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eIndex, 902\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eColor plate section facing p.522\u003c\/i\u003e\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49406892441943,"sku":"9781118589212","price":137.66,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781118589212.jpg?v=1730497466","url":"https:\/\/bookcurl.com\/products\/cancer-consult-9781118589212","provider":"Book Curl","version":"1.0","type":"link"}